Display options
Cite
Skagen C, Nyman TA, Peng XR, et al. Chronic treatment with terbutaline increases glucose and oleic acid oxidation and protein synthesis in cultured human myotubes. Curr Res Pharmacol Drug Discov. 2021;2:100039doi: 10.1016/j.crphar.2021.100039.
Skagen, C., Nyman, T. A., Peng, X. R., O'Mahony, G., Kase, E. T., Rustan, A. C., & Thoresen, G. H. (2021). Chronic treatment with terbutaline increases glucose and oleic acid oxidation and protein synthesis in cultured human myotubes. Current research in pharmacology and drug discovery, 2100039. https://doi.org/10.1016/j.crphar.2021.100039
Skagen, Christine, et al. "Chronic treatment with terbutaline increases glucose and oleic acid oxidation and protein synthesis in cultured human myotubes." Current research in pharmacology and drug discovery vol. 2 (2021): 100039. doi: https://doi.org/10.1016/j.crphar.2021.100039
Skagen C, Nyman TA, Peng XR, O'Mahony G, Kase ET, Rustan AC, Thoresen GH. Chronic treatment with terbutaline increases glucose and oleic acid oxidation and protein synthesis in cultured human myotubes. Curr Res Pharmacol Drug Discov. 2021 Jun 11;2:100039. doi: 10.1016/j.crphar.2021.100039. eCollection 2021. PMID: 34909668; PMCID: PMC8663959.
Copy Download .nbib Format: NLM
Share it on

Curr Res Pharmacol Drug Discov. 2021 Jun 11;2:100039. doi: 10.1016/j.crphar.2021.100039. eCollection 2021.

Chronic treatment with terbutaline increases glucose and oleic acid oxidation and protein synthesis in cultured human myotubes.

Current research in pharmacology and drug discovery

Christine Skagen, Tuula A Nyman, Xiao-Rong Peng, Gavin O'Mahony, Eili Tranheim Kase, Arild Chr Rustan, G Hege Thoresen

Affiliations

  1. Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Norway.
  2. Department of Immunology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Norway.
  3. Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  4. Medicinal Chemsitry, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  5. Department of Pharmacology, Institute of Clinical Medicine, University of Oslo, Norway.

PMID: 34909668 PMCID: PMC8663959 DOI: 10.1016/j.crphar.2021.100039

Abstract

METHODS: Human cultured myotubes were exposed to terbutaline in various concentrations (0.01-30 ​μM) for 4 or 96 ​h. Thereafter uptake of [

RESULTS: The results showed that 4 ​h treatment with terbutaline in concentrations up to 1 ​μM increased glucose uptake in human myotubes, but also decreased both glucose and oleic acid oxidation along with oleic acid uptake in concentrations of 10-30 ​μM. Moreover, administration of terbutaline for 96 ​h increased glucose uptake (in terbutaline concentrations up to 1 ​μM) and oxidation (1 ​μM), as well as oleic acid oxidation (0.1-30 ​μM), leucine incorporation into cellular protein (1-10 ​μM) and upregulated several pathways related to mitochondrial metabolism (1 ​μM). Data are available via ProteomeXchange with identifier PXD024063.

CONCLUSION: These results suggest that β

© 2021 The Authors.

Keywords: Adrenergic receptor (AR), Cyclic AMP (cAMP); Beta adrenergic receptor; Deoxyglucose (DOG), protein-coupled receptor (GPCR); Energy metabolism; Mammalian target of Rapamycin (mTOR), Oleic acid (OA); Mitochondrial metabolism; Myotubes; Oxidation; Protein Kinase A (PKA), Scintillation Proximity Assay (SPA); Type 2 diabetes (T2D), Trichloroacetic acid (TCA)

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Xiao-Rong Peng and Gavin O'Mahony are employees of AstraZeneca an

Publication Types